Previous close | 0.7397 |
Open | 0.7371 |
Bid | 0.6905 x 4000 |
Ask | 0.7799 x 1100 |
Day's range | 0.6918 - 0.7549 |
52-week range | 0.6918 - 3.4400 |
Volume | |
Avg. volume | 612,826 |
Market cap | 77.671M |
Beta (5Y monthly) | 1.44 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.0950 |
Earnings date | 08 May 2023 - 12 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.38 |
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.
DURHAM, N.C., March 02, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2022 and provide a business update on March 9, 2023.